1. Home
  2. LGCL vs CRBP Comparison

LGCL vs CRBP Comparison

Compare LGCL & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCL
  • CRBP
  • Stock Information
  • Founded
  • LGCL 2009
  • CRBP 2009
  • Country
  • LGCL China
  • CRBP United States
  • Employees
  • LGCL N/A
  • CRBP 28
  • Industry
  • LGCL
  • CRBP Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGCL
  • CRBP Health Care
  • Exchange
  • LGCL NYSE
  • CRBP Nasdaq
  • Market Cap
  • LGCL 119.4M
  • CRBP 110.3M
  • IPO Year
  • LGCL 2024
  • CRBP N/A
  • Fundamental
  • Price
  • LGCL $0.83
  • CRBP $9.26
  • Analyst Decision
  • LGCL
  • CRBP Strong Buy
  • Analyst Count
  • LGCL 0
  • CRBP 10
  • Target Price
  • LGCL N/A
  • CRBP $53.56
  • AVG Volume (30 Days)
  • LGCL 179.0K
  • CRBP 210.6K
  • Earning Date
  • LGCL 01-01-0001
  • CRBP 08-05-2025
  • Dividend Yield
  • LGCL N/A
  • CRBP N/A
  • EPS Growth
  • LGCL N/A
  • CRBP N/A
  • EPS
  • LGCL 0.07
  • CRBP N/A
  • Revenue
  • LGCL $145,690,427.00
  • CRBP N/A
  • Revenue This Year
  • LGCL N/A
  • CRBP N/A
  • Revenue Next Year
  • LGCL N/A
  • CRBP $270.04
  • P/E Ratio
  • LGCL $12.12
  • CRBP N/A
  • Revenue Growth
  • LGCL N/A
  • CRBP N/A
  • 52 Week Low
  • LGCL $0.28
  • CRBP $4.64
  • 52 Week High
  • LGCL $3.31
  • CRBP $61.90
  • Technical
  • Relative Strength Index (RSI)
  • LGCL N/A
  • CRBP 64.95
  • Support Level
  • LGCL N/A
  • CRBP $8.48
  • Resistance Level
  • LGCL N/A
  • CRBP $9.23
  • Average True Range (ATR)
  • LGCL 0.00
  • CRBP 0.54
  • MACD
  • LGCL 0.00
  • CRBP 0.11
  • Stochastic Oscillator
  • LGCL 0.00
  • CRBP 90.70

About LGCL LUCAS GC LIMITED

Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: